Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERIES: Sildenafil in Severe Pulmonary Hypertension Secondary to Rheumatic Valvular Disease
NCT07462260Phase 3Completed
- Sponsor
- Sindh Institute of Cardiovascular Diseases
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ASP-001 in pulmonary hypertension (PH), sponsored by Sindh Institute of Cardiovascular Diseases. Started Aug 2025; status: completed.
02
Drugs
ASP-001
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07462260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462260.